CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A single center, open, single arm dose escalation phase I study to evaluate the safety,
tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical,
anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell
injection, as well as investigate RP2D.